Mark Currie

Questioner
DISC Type : c

Chair SAB at Prudentia Sciences

Boston, Massachusetts, United States

Overview

Dr. Mark Currie is a distinguished pharmaceutical leader and Venture Partner at Iaso Ventures, holding board positions at Sea Pharmaceuticals and Ironwood Pharmaceuticals. With a Ph. D. from Wake Forest University, his career is marked by senior R&D roles where he guided the development of novel therapies from discovery to market.

Outside of his primary professional focus, Mark has expressed a keen interest in environmental science, particularly in advancing the scientific understanding of coastal waters. He actively follows and encourages the work of teams dedicated to marine and coastal research, highlighting a passion that bridges science and nature.

His pioneering academic research on the guanylate cyclase-C (GC-C) pathway laid the foundation for the discovery of the blockbuster drug linaclotide (LINZESS).

Personality Overview

Value Seeker

Not Easily Convinced

Cautious & Analytical

They are more likely than others to negotiate on pricing and terms.  While they don't hesitate to ask questions, they are generally risk-averse and tend to be late adopters. They prefer to do thorough analysis of any situation.

Topics They Care About

CNS Drug Development
He has a stated focus on the high unmet medical need in CNS diseases like epilepsy and ALS, specifically mentioning novel approaches targeting the glutamate pathway.
First-in-Class Therapeutics
Through his board roles, he is actively involved with companies developing novel treatments, including first-in-class GIP antagonists and innovative anti-infectives.
Biotech Venture Investing
As a Venture Partner with Iaso Ventures, he is actively engaged in identifying and supporting promising new companies and technologies in the life sciences sector.

Media Appearances

Mark has no verified media appearances

Work History

8-2025
Chair SAB at Prudentia Sciences
1-2025
Chair SAB at Scaffold Therapeutics
1-2024
Venture Partner at Iaso Ventures
6-2023
Board Member at Antag Therapeutics
4-2019
Director Board Of Directors at Ironwood Pharmaceuticals

Education

1976 - 1980
Doctor of Philosophy - PhD from Wake Forest University School of Medicine
1972 - 1976
Bachelor of Science - BS from University of South Alabama

More Information

Social Presence :

Prographics :

Exp : 17 Location : Boston, Massachusetts, United States Job Level : Mid-senior Designation : Chair SAB at Prudentia Sciences
URL has been copied!

Insights For Selling To Mark

During A Call Or A Meeting

DO's

  • Tell them that you will come back if you don’t have a good answer for a question
  • Keep some extra margin in hand as they will likely negotiate the pricing
  • Emphasize on objective proof of ROI, help them do a thorough evaluation

DONT's

  • Don’t depend too much on anecdotal evidence, it reduces their confidence
  • Avoid phrases like ‘do not worry about’, ‘no one compares to’ etc.
  • Don’t overhype the product/pitch, keep it measured

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Mark is

  • Confidence that the product provides ROI, effective pricing and process adherence matter the most to them.

  • Will you ever get a clear answer from Mark

  • It doesn’t come naturally to them but they can say no if they are not convinced.

Insights For Deal Planning

    How fast (or slow) will Mark move?

  • They can move at a reasonable pace while making their decisions if they have the necessary information.

  • Can Mark take some risk or not?

  • They can take some risk if they are confident that they have analyzed the circumstances well.


You And Mark

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.